Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  selinexor
Find trials that include:  Any drugs shown
Results 1-25 of 27 for your search:
Start Over
Selinexor, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Pancreatic Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: 2013-133, NCI-2014-01249, 1403012942, NCT02178436
Selinexor (KPT-330) and Pegylated Liposomal Doxorubicin Hydrochloride For Relapsed or Refractory Multiple Myeloma
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC 17814, NCI-2014-02019, 14.07.0046, NCT02186834
Selinexor, Fludarabine Phosphate, and Cytarabine in Treating Younger Patients with Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndromes
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 24 and under
Trial IDs: SELHEM, NCI-2014-01704, NCT02212561
Cladribine, Cytarabine, and Filgrastim in Combination with Selinexor in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 70
Trial IDs: 201505084, NCI-2015-00828, NCT02416908
Selinexor and Docetaxel in Treating Patients with Recurrent or Metastatic Squamous Cell Lung Cancer
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14152, NCI-2015-01165, NCT02536495
A Phase 2 Study Evaluating the Efficacy and Safety of Selinexor (KPT-330) in Patients With Recurrent Gliomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-004, NCI-2014-01569, NCT01986348
Selinexor (KPT-330) in Older Patients With Relapsed AML
Phase: Phase II
Type: Treatment
Age: 60 and over
Trial IDs: KCP-330-008, NCI-2014-00820, NCT02088541
Selinexor in Initial or Relapsed/Refractory Richter's Transformation
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-010, NCI-2015-00013, NCT02138786
Study of Selinexor (KPT-330) in Metastatic Castrate Resistant Prostate Adenocarcinoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-007, NCI-2014-01236, NCT02146833
Selinexor in Treating Patients with Abiraterone Acetate and/or Enzalutamide Refractory Metastatic Castration-Resistant Prostate Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14552, NCI-2014-01936, NCT02215161
Study of Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (SADAL)
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-009, NCI-2014-02149, NCT02227251
Selinexor in Treating Patients with Myelodysplastic Syndromes Refractory to Hypomethylating Agents
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 14-005, NCI-2014-01914, NCT02228525
Phase 2b Open-Label Single-Arm Study With KPT-330 & Dexamethasone in Patients w/ Quad-refractory Multiple Myeloma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: KCP-330-012, NCI-2015-00666, NCT02336815
Selinexor in Treating Patients with Relapsed Small Cell Lung Cancer
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14136, NCI-2014-02489, NCT02351505
Phase 2 Trial of Selinexor for Metastatic Triple Negative Breast Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC 18150, NCI-2015-01166, NCT02402764
Safety Study of the Selective Inhibitor of Nuclear Export (SINE) KPT-330 in Patients With Advanced Hematological Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: KCP-330-001, NCI-2012-03045, NCT01607892
Selinexor in Treating Younger Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 months to 21 years
Trial IDs: 13-563, NCI-2014-00936, NCT02091245
Decitabine and Selinexor in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: OSU-13182, NCI-2014-00559, 2014C0005, NCT02093403
Selinexor, Carfilzomib, and Dexamethasone in Treating Patients with Relapsed/Refractory Multiple Myeloma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IRB14-0033, NCI-2014-01199, NCT02199665
Selinexor and Irinotecan Hydrochloride in Treating Patients with Stomach or Distal Esophageal Cancer That is Recurrent, Metastatic, or Cannot Be Removed by Surgery
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 17919, NCI-2014-02530, 14.11.0001, MCC 17919, NCT02283359
Selinexor and Chemotherapy in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU 14089, NCI-2014-02229, NCT02299518
Selinexor and Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14087, NCI-2014-01493, NCT02303392
Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 21
Trial IDs: ADVL1414, NCI-2014-02410, NCT02323880
A Study of Selinexor in Combination with Daunorubicin and Cytarabine for Untreated Acute Myeloid Leukemia (AML)
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: MCC 18157, NCI-2015-00988, 15.05.0004, NCT02403310
Start Over